Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Adicet Bio, Inc. (ACET) Insider Trading Activity
Healthcare • Biotechnology • 143 employees
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Total Value
-$47,641.39
Total Shares
-51,683
Average Trade Value
-$11,910.35
Most Active Insider
Schor Chen
Total Activity: $25,904
Largest Single Transaction
$25,904
by Schor Chen on Jan 24, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President CEO
|
Jan 24, 2025 | 28,101 | $25,904 | 137,201 (-20.5%) | Payment of Exercise Price | |
|
Chief Technology Officer
|
Jan 24, 2025 | 8,560 | $7,891 | 63,769 (-13.4%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Jan 24, 2025 | 8,752 | $8,068 | 91,048 (-9.6%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 24, 2025 | 6,270 | $5,780 | 56,241 (-11.1%) | Payment of Exercise Price |